Abiopharma

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

New Form 8-K - ZyVersa Therapeutics, Inc. Filed: 2025-06-25 AccNo: 0001641172-25-016388 Size: 674 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 4 - Silence Therapeutics plc Filed: 2025-06-25 AccNo: 0001104659-25-062407 Size: 9 KB

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

FDA Grants RMAT Designation for enGenes Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

New Form 8-K - Quoin Pharmaceuticals, Ltd. Filed: 2025-06-25 AccNo: 0001104659-25-062406 Size: 188 KB Item 8.01: Other Events

New Form 8-K - Glucotrack, Inc. Filed: 2025-06-25 AccNo: 0001641172-25-016387 Size: 245 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Silo Pharma Notification (SILO)

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

New Form 25-NSE - Regulus Therapeutics Inc. Filed: 2025-06-25 AccNo: 0001354457-25-000571 Size: 3 KB

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Tivic Health Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer